GlassScriptPhysician profile
Victoria Murad
NPI 1669141362
$1,536.69
in general payments reported to CMS, 2019-2025
23 companies · $597 in 2025
The $597 reported for 2025 was more than what 78% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.54 · 2022: $233 · 2023: $327 · 2024: $362 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $264.95 | 2022-2025 | Entyvio, Hyqvia, Gammagard |
| Janssen Scientific Affairs, LLC | $240.62 | 2025 | Tremfya |
| Abbvie INC. | $157.48 | 2023-2025 | |
| Tg Therapeutics, INC. | $149.94 | 2025 | |
| Alexion Pharmaceuticals, INC. | $119.88 | 2023-2025 | Soliris, Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.35 | 2021-2022 | |
| Lundbeck LLC | $85.65 | 2022-2025 | Vyepti |
| Horizon Therapeutics Plc | $67.77 | 2023 | Uplizna, Tepezza, Krystexxa |
| Genentech USA, INC. | $41.98 | 2022-2024 | Ocrevus |
| Argenx US, INC. | $39.82 | 2024 | |
| Melinta Therapeutics, LLC | $36.57 | 2022-2024 | Rezzayo |
| Eisai INC. | $33.29 | 2023-2024 | |
| Grifols USA, LLC | $26.15 | 2023 | Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.37 | 2024 | Spevigo |
| Pfizer INC. | $23.23 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $19.91 | 2023 | Renflexis |
| Pharmacosmos Therapeutics INC. | $19.87 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $18.65 | 2022 | |
| Daiichi Sankyo INC. | $17.06 | 2022 | |
| Lilly USA, LLC | $16.86 | 2024 | Omvoh |
| Collegium Pharmaceutical, INC. | $16.28 | 2022 | |
| Merck Sharp & Dohme LLC | $15.29 | 2022 | |
| Grt US Holding, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.